Similar articles for PMID: 28835379

Year	Number of Results
2002	1
2008	2
2009	1
2010	1
2011	2
2012	8
2013	8
2014	12
2015	15
2016	27
2017	46
2018	47
2019	72
2020	37
2021	25
2022	13
2023	5
2024	0

1

Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research.

Kidwell KM, Postow MA, Panageas KS. Kidwell KM, et al. Clin Cancer Res. 2018 Feb 15;24(4):730-736. doi: 10.1158/1078-0432.CCR-17-1355. Epub 2017 Aug 23. Clin Cancer Res. 2018. PMID: 28835379 Free PMC article.

2

Combination therapy with PD-1 or PD-L1 inhibitors for cancer.

Hayashi H, Nakagawa K. Hayashi H, et al. Int J Clin Oncol. 2020 May;25(5):818-830. doi: 10.1007/s10147-019-01548-1. Epub 2019 Sep 23. Int J Clin Oncol. 2020. PMID: 31549270 Review.

3

Inhibitors of Cytotoxic T Lymphocyte Antigen 4 and Programmed Death 1/Programmed Death 1 Ligand for Metastatic Melanoma, Dual Versus Monotherapy-Summary of Advances and Future Directions for Studying These Drugs.

Loo K, Daud AI. Loo K, et al. Cancer J. 2017 Jan/Feb;23(1):3-9. doi: 10.1097/PPO.0000000000000238. Cancer J. 2017. PMID: 28114249 Review.

4

The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Mahoney KM, Freeman GJ, McDermott DF. Mahoney KM, et al. Clin Ther. 2015 Apr 1;37(4):764-82. doi: 10.1016/j.clinthera.2015.02.018. Epub 2015 Mar 29. Clin Ther. 2015. PMID: 25823918 Free PMC article. Review.

5

Next steps in immuno-oncology: enhancing antitumor effects through appropriate patient selection and rationally designed combination strategies.

Salama AK, Moschos SJ. Salama AK, et al. Ann Oncol. 2017 Jan 1;28(1):57-74. doi: 10.1093/annonc/mdw534. Ann Oncol. 2017. PMID: 28177433 Free PMC article. Review.

6

Immune checkpoint blockade.

Naidoo J, Page DB, Wolchok JD. Naidoo J, et al. Hematol Oncol Clin North Am. 2014 Jun;28(3):585-600. doi: 10.1016/j.hoc.2014.02.002. Hematol Oncol Clin North Am. 2014. PMID: 24880949 Review.

7

Combining forces: the promise and peril of synergistic immune checkpoint blockade and targeted therapy in metastatic melanoma.

Hermel DJ, Ott PA. Hermel DJ, et al. Cancer Metastasis Rev. 2017 Mar;36(1):43-50. doi: 10.1007/s10555-017-9656-2. Cancer Metastasis Rev. 2017. PMID: 28181070 Review.

8

Melanoma: smart therapeutic strategies in immuno-oncology.

Eggermont AM, Robert C. Eggermont AM, et al. Nat Rev Clin Oncol. 2014 Apr;11(4):181-2. doi: 10.1038/nrclinonc.2014.36. Epub 2014 Mar 4. Nat Rev Clin Oncol. 2014. PMID: 24590131 No abstract available.

9

Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.

Gide TN, Quek C, Menzies AM, Tasker AT, Shang P, Holst J, Madore J, Lim SY, Velickovic R, Wongchenko M, Yan Y, Lo S, Carlino MS, Guminski A, Saw RPM, Pang A, McGuire HM, Palendira U, Thompson JF, Rizos H, Silva IPD, Batten M, Scolyer RA, Long GV, Wilmott JS. Gide TN, et al. Cancer Cell. 2019 Feb 11;35(2):238-255.e6. doi: 10.1016/j.ccell.2019.01.003. Cancer Cell. 2019. PMID: 30753825 Free article.

10

Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.

Herzberg B, Campo MJ, Gainor JF. Herzberg B, et al. Oncologist. 2017 Jan;22(1):81-88. doi: 10.1634/theoncologist.2016-0189. Epub 2016 Aug 17. Oncologist. 2017. PMID: 27534574 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

291 results

Results by year